These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
639 related articles for article (PubMed ID: 34742312)
1. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Zhu G; Pei L; Xia H; Tang Q; Bi F Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312 [TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
3. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899 [TBL] [Abstract][Full Text] [Related]
4. The current understanding on the impact of KRAS on colorectal cancer. Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280 [TBL] [Abstract][Full Text] [Related]
5. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718 [TBL] [Abstract][Full Text] [Related]
6. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL Cells; 2019 Dec; 8(12):. PubMed ID: 31816869 [TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012 [TBL] [Abstract][Full Text] [Related]
9. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis. Xie W; Xie L; Song X Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218 [TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine. Sahin IH; Saridogan T; Ayasun R; Syed MP; Gorantla V; Malhotra M; Thomas R; Rhee J; Zhang J; Hsu D; Singhi AD; Saeed A JCO Oncol Pract; 2024 Oct; 20(10):1336-1347. PubMed ID: 38739872 [No Abstract] [Full Text] [Related]
14. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer. Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762 [TBL] [Abstract][Full Text] [Related]
15. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711 [TBL] [Abstract][Full Text] [Related]
17. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Morkel M; Riemer P; Bläker H; Sers C Oncotarget; 2015 Aug; 6(25):20785-800. PubMed ID: 26299805 [TBL] [Abstract][Full Text] [Related]
18. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063 [TBL] [Abstract][Full Text] [Related]
19. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1. Yuan M; Zhang C; Chen S; Ye S; Liu H; Ke H; Huang J; Liang G; Yu R; Hu T; Wu X; Lan P Cancer Lett; 2024 Aug; 597():217007. PubMed ID: 38849010 [TBL] [Abstract][Full Text] [Related]
20. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors. Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]